glp-1 agonist and dpp-4 inhibitor inhibitors GLP-1RAs: cardiovascular safety and benefits | Military Medical Research GLP-1-based therapies, including GLP-1, GLP-1R

Tuttle, R

L., Li, Y., & Lu, H

Patients should be counselled that regaining weight after stopping GLP-1 RAs can reverse improvements, potentially requiring medications to be resumed

Understanding how these two agents might work together could inform dietary strategies for patients receiving GLP-1 receptor agonist treatment, though it is important to note that research in this area remains in relatively early stages

Discontinuation rates in randomized CV outcome trials As presented in Table 4, some patients randomized to GLP-1 RA treatment discontinued the assigned medication

Coronary Revascularization Procedures Trials including LEADER, AMPLITUDE-O, and REWIND found no effect of GLP-1 RAs on the risk of coronary revascularization (Marso et al., 2016